1. Home
  2. NCMI vs CHRS Comparison

NCMI vs CHRS Comparison

Compare NCMI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$2.27

Market Cap

207.0M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.14

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
CHRS
Founded
2005
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.0M
177.7M
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
NCMI
CHRS
Price
$2.27
$1.14
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
★ $5.63
$5.51
AVG Volume (30 Days)
861.8K
★ 1.1M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
★ 3.36%
N/A
EPS Growth
52.17
★ 472.00
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$11.20
$73.08
Revenue Next Year
$6.22
$30.94
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.11
$1.09
52 Week High
$4.67
$2.62

Technical Indicators

Market Signals
Indicator
NCMI
CHRS
Relative Strength Index (RSI) 36.79 37.82
Support Level $2.16 N/A
Resistance Level $3.72 $1.53
Average True Range (ATR) 0.11 0.09
MACD 0.02 -0.02
Stochastic Oscillator 39.24 0.00

Price Performance

Historical Comparison
NCMI
CHRS

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: